This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of ARC1779 in Patients With Acute Myocardial Infarction Undergoing PCI (vITAL-1)

This study has been terminated.
Information provided by:
Archemix Corp. Identifier:
First received: July 24, 2007
Last updated: January 8, 2009
Last verified: January 2009
ARC1779 is a novel drug being tested in patients undergoing angioplasty and stenting as their primary treatment for heart attack.

Condition Intervention Phase
Acute Myocardial Infarction Procedure: PCI Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of an Aptameric Von Willebrand Factor Antagonist, ARC1779, in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Resource links provided by NLM:

Further study details as provided by Archemix Corp.:

Primary Outcome Measures:
  • adequacy of reperfusion [ Time Frame: 48 hours post-PCI ]

Secondary Outcome Measures:
  • bleeding [ Time Frame: PCI to hospital discharge ]

Estimated Enrollment: 300
Study Start Date: October 2007
Study Completion Date: February 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ARC1779 low dose
0.1 mg/kg
Procedure: PCI
early PCI for NSTEMI; primary PCI for STEMI
Experimental: ARC1779 mid dose
0.3 mg/kg
Procedure: PCI
early PCI for NSTEMI; primary PCI for STEMI
Experimental: ARC1779 high dose
1.0 mg/kg
Procedure: PCI
early PCI for NSTEMI; primary PCI for STEMI
Active Comparator: abciximab
labeled regimen for primary PCI
Procedure: PCI
early PCI for NSTEMI; primary PCI for STEMI

Detailed Description:
Adjunctive anti-thrombotic therapy for PCI of AMI may be improved by incorporation of a novel anti-platelet therapeutic principle, von Willebrand Factor antagonism. ARC1779 is a therapeutic oligonucleotide ("aptamer") which blocks the binding of the A1 domain of vWF to the platelet GPIb receptor, and thereby modulates platelet adhesion, activation, and aggregation under the high shear conditions of coronary arterial stenosis and plaque rupture. This study is intended to provide dose-ranging and clinical proof of concept for ARC1779 in a primary PCI population.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • troponin-positive NSTEMI, with diagnostic symptoms and/or ECG abnormalities present within the preceding 24 hours, and a planned "early invasive" management strategy
  • STEMI, with planned primary PCI

Exclusion Criteria:

  • History of bleeding diathesis or evidence of active abnormal bleeding within the previous 30 days
  • Received treatment with fibrinolytic or GPIIb/IIIa antagonist drugs within the preceding 72 hours
  • Received anticoagulant therapy with a low molecular weight heparin within the preceding 8 hours
  • Severe hypertension (systolic blood pressure >200 mmHg or diastolic blood pressure >110 mmHg) not adequately controlled on antihypertensive therapy
  • Major surgery or trauma within the preceding 6 weeks
  • History of stroke within 30 days or any history of hemorrhagic stroke
  • End-stage renal disease (ESRD) with dependency on renal dialysis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00507338

Russian Federation
Archemix Investigational Site
St. Petersburg, Russia, Russian Federation, 199106
Sponsors and Collaborators
Archemix Corp.
Study Chair: Michael Gibson, MD Harvard Medical School, Beth Israel Deaconess Medical Center
Principal Investigator: Franz-Josef Neumann, MD Herz-Zentrum Bad Krozingen
  More Information

Responsible Party: James Gilbert, MD/Chief Medical Officer, Archemix, Corp. Identifier: NCT00507338     History of Changes
Other Study ID Numbers: ARC1779-003
Study First Received: July 24, 2007
Last Updated: January 8, 2009

Keywords provided by Archemix Corp.:
percutaneous coronary intervention

Additional relevant MeSH terms:
Myocardial Infarction
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases processed this record on June 22, 2017